AR057681A1 - Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores - Google Patents

Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores

Info

Publication number
AR057681A1
AR057681A1 ARP060103177A ARP060103177A AR057681A1 AR 057681 A1 AR057681 A1 AR 057681A1 AR P060103177 A ARP060103177 A AR P060103177A AR P060103177 A ARP060103177 A AR P060103177A AR 057681 A1 AR057681 A1 AR 057681A1
Authority
AR
Argentina
Prior art keywords
substituted
alkenyl
alkyls
halogen
hydrogen
Prior art date
Application number
ARP060103177A
Other languages
English (en)
Inventor
Michael A Palladino
Emmanuel A Theodorakis
Venkat Rami Reddy Macherla
Ta-Hsiang Chao
Young Ger Suh
Original Assignee
Nereus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc filed Critical Nereus Pharmaceuticals Inc
Publication of AR057681A1 publication Critical patent/AR057681A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/557—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la siguiente estructura química (1): (IIBB) en donde: R2 se selecciona entre el grupo formado por hidrogeno, un halogeno, COOH, ácidos C1-12 carboxílicos, haluros de C1-12 acilo, residuos C1-12 acilo, C1-12 ésteres, C1-12 amidas secundarias, (C1-12)(C1-12) amidas terciarias, (C1-12) amidas cíclicas, C1-12) aminas, C1-12 alcoholes, (C1-12)(C1-12) éteres, C1-12 alquilos, C1-12 alquilos sustituidos, C2-12 alquenilos, C2-12 alquenilos sustituidos, y C5-12 arilos; R17 se selecciona entre C5-12 alquilos cíclicos; C5-12 alquenilos cíclicos; C5-12 alquilos cíclicos sustituidos, C5-12 alquenilos cíclicos sustituidos; fenilo y C5-12 arilos; R9 se selecciona entre hidrogeno,un halogeno, C1-12 alquilo, C1-12 alquilos sustituidos, C2-12 alquenilo, C2-12 alquenilo sustituido, C2-12 alquinilo, C1-12 alcohol, C1-12 acilo, y C5-12 arilo; R3-R5, R7, R8 y R11-R13 se seleccionan cada uno por separado entre hidrogeno, un halogeno, C1-12 alquilo, C1-12 alquilos sustituidos, C2-12 alquenilo, C2-12 alquenilo sustituido, C2-12 alquinilo, y C5-12 arilo; R6 se selecciona entre hidrogeno, un halogeno, C1-12 alquilo, C1-12 alquilos sustituidos, C2-12 alquenilo, C2-12 alquenilo sustituido, y C2-12 alquinilo; R10 se selecciona ente hidrogeno, un halogeno, CH2, C1-6 alquilo, C1-6 alquilo sustituido, C2-6 alquenilo, C2-6 alquenilo sustituido, C1-12 alcohol, y C5-12 arilo; R14 y R15 se seleccionan por separado entre hidrogeno, un halogeno CH2, C1-6 alquilo, C1-6 alquilo sustituido, C2-6 alquenilo, C2-6 alquenilo sustituido, C1-6 alcohol, y C5-6 arilo; y R16 se selecciona entre el grupo formado por un hidrogeno, un halogeno, COOH, ácidos C1-12 carboxílicos, haluros de C1-C12 acilo, residuos C1-12 acilo, C1-12 ésteres, C1-12 amidas secundarias, (C1-12)(C1-12) amidas terciarias, (C1-12) amidas cíclicas, (C1-12) aminas, C1-12 alcoholes, (C1-12)(C1-12) éteres, C1-12 alquilos, C1-12 alquilos sustituidos, C2- 12 alquenilos, C2-12 alquenilos sustituidos, y C5-12 arilos; en donde el compuesto incluye los ésteres prodroga de los compuestos precedentes, y sus sales de adicion ácida. Que son utiles como moduladores de Interleuquina-1 y Factor-alfa de Necrosis Tumoral, y por lo tanto son utiles en el tratamiento de diversas enfermedades, donde los grupos R se definen en las reivindicaciones.
ARP060103177A 2005-07-21 2006-07-21 Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores AR057681A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70193205P 2005-07-21 2005-07-21
US73459005P 2005-11-07 2005-11-07
US73467905P 2005-11-07 2005-11-07
US74954205P 2005-12-12 2005-12-12
US78522306P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
AR057681A1 true AR057681A1 (es) 2007-12-12

Family

ID=37497889

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103177A AR057681A1 (es) 2005-07-21 2006-07-21 Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores

Country Status (11)

Country Link
US (3) US7893299B2 (es)
EP (2) EP2311795A3 (es)
JP (1) JP2009505954A (es)
KR (1) KR20080035650A (es)
AR (1) AR057681A1 (es)
AT (1) ATE556046T1 (es)
AU (1) AU2006276274B2 (es)
CA (1) CA2613366A1 (es)
IL (1) IL188353A0 (es)
TW (1) TW200744992A (es)
WO (1) WO2007015757A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101591482B1 (ko) 2008-05-28 2016-02-03 레베라겐 바이오파마 인코포레이티드 질환의 치료를 위한 ＮＦ-κＢ 의 비호르몬성 스테로이드 조절제
EA201190178A1 (ru) * 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
SG189159A1 (en) * 2010-10-27 2013-05-31 Sigma Tau Ind Farmaceuti Diterpenoid derivatives endowed of biological properties
CA2855756A1 (en) * 2011-11-29 2013-06-06 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US10494397B2 (en) * 2016-07-15 2019-12-03 Pepsico, Inc. Rebaudioside analogs
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
RU2726613C1 (ru) * 2019-12-16 2020-07-15 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Карбоксамиды изопимаровой кислоты, обладающие анальгетической активностью

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5212708B2 (es) 1974-05-14 1977-04-08
JPS522910B2 (es) * 1974-05-17 1977-01-25
GB1452053A (en) 1974-08-28 1976-10-06 Nippon Shinyaku Co Ltd Abietamide derivatives and a method for the preparation thereof
US4874891A (en) 1986-05-01 1989-10-17 Washington University Open "D" ring hormone analogs
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DK0472733T3 (da) 1990-03-06 1995-03-13 Otsuka Pharma Co Ltd Phenantrenderivater
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
EP0674510B1 (en) 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
RU2150942C1 (ru) 1993-10-01 2000-06-20 Синтекс (Ю.ЭС.ЭЙ.) Инк. Оральные суспензии, содержащие высокие дозы мофетила микофенолята
KR0145941B1 (ko) 1994-06-13 1998-08-17 김은영 인터루킨-1과 종양 괴사 인자-알파의 생산 억제에 유용한 아칸토산을 포함하는 약학적 조성물
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
NL1001681C2 (nl) 1995-11-17 1997-05-21 Geesink Bv Voertuig, in het bijzonder een afvalinzamelvoertuig, voorzien van een veiligheidssysteem.
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DE69913497T2 (de) 1998-01-26 2004-09-16 Sae Han Pharm. Co., Ltd. Diterpenderivate und entzündungshemmende schmerzmittel die diese enthalten
US6051590A (en) 1999-05-13 2000-04-18 Merck & Co., Inc. Immunosuppressant tricyclic compounds
NZ515675A (en) 1999-05-14 2004-06-25 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
WO2002079137A1 (en) 2001-03-28 2002-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
DE102004035203A1 (de) * 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone

Also Published As

Publication number Publication date
JP2009505954A (ja) 2009-02-12
EP2311795A3 (en) 2011-12-28
EP2311795A2 (en) 2011-04-20
ATE556046T1 (de) 2012-05-15
AU2006276274A1 (en) 2007-02-08
KR20080035650A (ko) 2008-04-23
CA2613366A1 (en) 2007-02-08
US7893299B2 (en) 2011-02-22
US20120238634A1 (en) 2012-09-20
WO2007015757A3 (en) 2007-06-21
EP1912932A2 (en) 2008-04-23
WO2007015757A2 (en) 2007-02-08
EP1912932B1 (en) 2012-05-02
IL188353A0 (en) 2008-04-13
US8133915B2 (en) 2012-03-13
TW200744992A (en) 2007-12-16
US20110160309A1 (en) 2011-06-30
AU2006276274B2 (en) 2012-03-29
US20080064753A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
AR057681A1 (es) Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
PE20050476A1 (es) Compuestos de pirrol y pirazol
CO5560575A2 (es) Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR057712A1 (es) Dihidropteridinonas en el tratamiento de enfermedades respiratorias
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR035883A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
CO5631432A2 (es) Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR042437A1 (es) Derivados de fluoroglicosidos heterociclicos, medicamentos que los contienen y usos
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
ECSP11010857A (es) Nuevas benzamidas, su preparación y su uso como medicamentos
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR070578A1 (es) Imidazolidinas fenil- sustituidas, medicamentos que comprenden dichos compuestos y su uso para producir medicamentos
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR082498A1 (es) Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide
AR082507A1 (es) Compuestos de tetrahidrofuranilo, medicamento en base al compuesto y un procedimiento para la fabricacion del medicamento
UY28879A1 (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure